CLINICAL IMPLICATIONS OF NIVOLUMAB IN CANCER IMMUNOTHERAPY

• In: Poster Session
• At: Düsseldorf (Germany) (2015)
• Type: Poster
• By: KUCUK, Esra (Hacettepe University Faculty of Pharmacy, Clinical Pharmacy, Ankara, Turkey)
• Co-author(s): Esra KUCUK
  Ecz. Burcu Kelleci, Hacettepe Universitesi Eczacilik Fakultesi Klinik Eczacilik Anabilim Dali
  
• Abstract:

  A cancer treatment recently focuses on immunotherapy such as nivolumab, ipilimumab and pembrolizumab.

  We searched through the Pub-Med database (between 2010-2015) by using nivolumab and immunotherapy as keywords.

  Nivolumab is administered via iv infusion over an hour at the dose of 2-3mg/kg for every 2-3 weeks. Drug must be constituted with 0,9%

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login